Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats.
Intestinal mucositis is a common toxic side effect in cancer patients receiving high-dose chemotherapy. This study aimed to evaluate the beneficial effects of Bifidobacterium infantis in a rat model of intestinal mucositis induced by 5-fluorouracil (5-FU). Thirty male Sprague-Dawley rats were divided into three groups: control, 5-FU, and 5-FU + B. infantis. A single intraperitoneal injection of 5-FU (150 mg/kg) was used to induce intestinal mucositis. B. infantis (1×109 cfu) was administered for 11 days, starting from 7 days before 5-FU injection. Intestinal mucositis was evaluated based on body weight, villus height, immunohistological expression of proliferating cell nuclear antigen (PCNA) and nuclear factor kappa beta (NF-κB), levels of the pro-inflammatory factors interleukin 1 beta and tumour necrosis factor alpha, and myeloperoxidase (MPO) concentration. The results showed that the 5-FU + B. infantis group demonstrated a higher body weight and villus height, increased expression of PCNA, reduced expression of NF-κB and pro-inflammatory factors, and lower MPO concentration compared to the 5-FU group. These data suggest that probiotic B. infantis is effective in reducing chemotherapy-induced intestinal mucositis in rats.
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
K-T
KT
Yuan
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
H-L
HL
Yu
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
W-D
WD
Feng
Department of Oral and Maxillofacial Surgery, Shanghai Ninth People-s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Huangpu, 200011 Shanghai, China P.R.
P
P
Chong
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
T
T
Yang
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
C-L
CL
Xue
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
M
M
Yu
Department of General Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, 510080 Guangzhou, China P.R.
H-P
HP
Shi
D000818:Animals; D001644:Bifidobacterium / Q000254:growth & development*; D015415:Biomarkers; D001835:Body Weight; D005472:Fluorouracil / Q000009:adverse effects*; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000473:pathology; D052016:Mucositis / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D019936:Probiotics / Q000008:administration & dosage*; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome
D015415:Biomarkers; D005472:Fluorouracil
5-fluorouracil; Bifidobacterium infantis; chemotherapy; mucositis; probiotic